Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts
- PMID: 10511310
Loss of cell cycle control by deregulation of cyclin-dependent kinase 2 kinase activity in Evi-1 transformed fibroblasts
Abstract
The Evi-1 transcriptional repressor protein has two distinct zinc finger DNA binding domains designated ZF1 and ZF2 and is implicated in the progression of human and murine leukemias, in which it is abnormally expressed. In this report, we show that Evi-1-expressing Rat1 fibroblasts are anchorage independent, have an abbreviated G1 phase of the cell cycle, and have a reduced requirement for serum mitogens for S-phase entry. These biological changes are accompanied by a moderately increased production of cell cycle-regulatory proteins cyclin A and cyclin-dependent kinase (Cdk) 2, a dramatic deregulation of Cdk2 kinase activity, and a corresponding increase in the levels of hyperphosphorylated retinoblastoma protein (pRb). We show that the elevated cyclin A-Cdk2 activity is due to the combination of increased accumulation and stabilization of cyclin A bound to a faster-migrating species of Cdk2 believed to be the active threonine 160 phosphorylated form and a substantial reduction in complexed p27. Cyclin E kinase activity is also elevated due to a reduction in p27. A significant reduction in total cellular p27 protein levels and a moderate reduction in p27 mRNA are observed, but no changes in Cdk regulatory kinases and phosphatases occur. The Evi-1 transcriptional repressor domain and the ZF1 DNA binding domain are required for both cell transformation and induction of Cdk2 catalytic activity. We propose that one consequence of Evi-1 expression is to repress the transcription of target genes, which may include p27, that deregulate the normal control of the G1 phase of the cell cycle, providing a cellular proliferative advantage that contributes to transformation in vitro and leukemogenesis in vivo.
Similar articles
-
Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.Oncogene. 1998 May;16(20):2575-83. doi: 10.1038/sj.onc.1201791. Oncogene. 1998. PMID: 9632134
-
Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F.Nature. 1997 May 22;387(6631):422-6. doi: 10.1038/387422a0. Nature. 1997. PMID: 9163430
-
CaMK-II inhibition reduces cyclin D1 levels and enhances the association of p27kip1 with Cdk2 to cause G1 arrest in NIH 3T3 cells.Exp Cell Res. 1998 May 1;240(2):218-27. doi: 10.1006/excr.1997.3925. Exp Cell Res. 1998. PMID: 9596994
-
Cyclin-dependent kinases and S phase control in mammalian cells.Cell Cycle. 2003 Jul-Aug;2(4):316-24. Cell Cycle. 2003. PMID: 12851482 Review.
-
The role of cyclin E in cell proliferation, development and cancer.Prog Cell Cycle Res. 1997;3:171-91. doi: 10.1007/978-1-4615-5371-7_14. Prog Cell Cycle Res. 1997. PMID: 9552414 Review.
Cited by
-
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.Breast Cancer Res. 2000;2(2):107-15. doi: 10.1186/bcr42. Epub 2000 Feb 21. Breast Cancer Res. 2000. PMID: 11250700 Free PMC article. Review.
-
EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.J Biol Chem. 2016 Jun 24;291(26):13591-607. doi: 10.1074/jbc.M115.708156. Epub 2016 Apr 21. J Biol Chem. 2016. PMID: 27129260 Free PMC article.
-
Phosphorylation of the leukemic oncoprotein EVI1 on serine 196 modulates DNA binding, transcriptional repression and transforming ability.PLoS One. 2013 Jun 12;8(6):e66510. doi: 10.1371/journal.pone.0066510. Print 2013. PLoS One. 2013. PMID: 23776681 Free PMC article.
-
Overexpression of EVI1 interferes with cytokinesis and leads to accumulation of cells with supernumerary centrosomes in G0/1 phase.Cell Cycle. 2012 Sep 15;11(18):3492-503. doi: 10.4161/cc.21801. Epub 2012 Aug 16. Cell Cycle. 2012. PMID: 22894935 Free PMC article.
-
RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks.Haematologica. 2021 Jun 1;106(6):1569-1580. doi: 10.3324/haematol.2019.241885. Haematologica. 2021. PMID: 32299907 Free PMC article.